Table 1.
Demographic and clinical baseline characteristics
| Amyloidosis (n = 11) |
Controls (n = 11) |
P-value | |
|---|---|---|---|
| Age (years) | 60.5 ± 11.4 | 62.9 ± 8.9 | 0.57 |
| Male (%) | 8 (73) | 8 (73) | 1.0 |
| BMI (g/m2) | 24.3 ± 2.9 | 24.2 ± 4.6 | 0.94 |
| AL-Amyloidosis | 7 (64) | – | – |
| Disease duration (years) | 2.19 ± 2.1 | – | – |
| Comorbidities | |||
| Diabetes, n(%) | 1 (9) | 0 (0) | 0.31 |
| Hypertension, n(%) | 4 (36) | 5 (45) | 0.66 |
| CAD, n(%) | 0 (0) | 0 (0) | 1.0 |
| Previous stroke, n(%) | 1 (9) | 0 (0) | 0.31 |
| Class NYHA III-IV n(%) | 2 (18) | 0 (0) | 0.14 |
| Biochemical | |||
| Cholesterol (mmol/L) | 5.9 ± 3.2 | 5.6 ± 1.0 | 0.794 |
| HDL (mmol/L) | 1.3 ± 0.5 | 1.5 ± 0.4 | 0.187 |
| Non-HDL (mmol/L) | 4.5 ± 3.4 | 4.0 ± 1.0 | 0.664 |
| LDL (mmol/L) | 2.7 ± 1.2 | 3.3 ± 0.8 | 0.234 |
| Triglycerides (mmol/L) | 2.5 ± 2.9 | 1.7 ± 0.9 | 0.358 |
| NT-proBNP (ng/L) | 1287 ± 1304 | – | – |
| Creatinine (μg/dL) | 110 ± 33.9 | – | – |
| Treatment | |||
| Stem cell transplantation | 4 (36) | – | – |
| Chemotherapy | 7 (64) | – | – |
| Green tea | 3 (27) | – | – |
AL amyloid light-chain, BMI body mass index, CAD coronary artery disease, GFR glomerular filtration rate, HDL high density lipoprotein, LDL low density lipoprotein, NYHA New York Heart Association, NT-proBNP N-terminal prohormone of brain natriuretic peptide-levels